149 related articles for article (PubMed ID: 16933358)
1. Aziridide-based inhibitors of cathepsin L: synthesis, inhibition activity, and docking studies.
Vicik R; Busemann M; Gelhaus C; Stiefl N; Scheiber J; Schmitz W; Schulz F; Mladenovic M; Engels B; Leippe M; Baumann K; Schirmeister T
ChemMedChem; 2006 Oct; 1(10):1126-41. PubMed ID: 16933358
[TBL] [Abstract][Full Text] [Related]
2. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
Schirmeister T
J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
[TBL] [Abstract][Full Text] [Related]
3. Aziridine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as inhibitors of cysteine proteases.
Martichonok V; Plouffe C; Storer AC; Ménard R; Jones JB
J Med Chem; 1995 Aug; 38(16):3078-85. PubMed ID: 7636871
[TBL] [Abstract][Full Text] [Related]
4. Aziridinyl peptides as inhibitors of cysteine proteases: effect of a free carboxylic acid function on inhibition.
Schirmeister T; Peric M
Bioorg Med Chem; 2000 Jun; 8(6):1281-91. PubMed ID: 10896108
[TBL] [Abstract][Full Text] [Related]
5. Azepanone-based inhibitors of human cathepsin L.
Marquis RW; James I; Zeng J; Trout RE; Thompson S; Rahman A; Yamashita DS; Xie R; Ru Y; Gress CJ; Blake S; Lark MA; Hwang SM; Tomaszek T; Offen P; Head MS; Cummings MD; Veber DF
J Med Chem; 2005 Nov; 48(22):6870-8. PubMed ID: 16250645
[TBL] [Abstract][Full Text] [Related]
6. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective and nonpeptidic cathepsin S inhibitors.
Irie O; Ehara T; Iwasaki A; Yokokawa F; Sakaki J; Hirao H; Kanazawa T; Teno N; Horiuchi M; Umemura I; Gunji H; Masuya K; Hitomi Y; Iwasaki G; Nonomura K; Tanabe K; Fukaya H; Kosaka T; Snell CR; Hallett A
Bioorg Med Chem Lett; 2008 Jul; 18(14):3959-62. PubMed ID: 18572405
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype.
Myers MC; Shah PP; Beavers MP; Napper AD; Diamond SL; Smith AB; Huryn DM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3646-51. PubMed ID: 18499453
[TBL] [Abstract][Full Text] [Related]
9. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.
Altmann E; Green J; Tintelnot-Blomley M
Bioorg Med Chem Lett; 2003 Jun; 13(12):1997-2001. PubMed ID: 12781182
[TBL] [Abstract][Full Text] [Related]
10. Aziridine-2,3-dicarboxylate-based cysteine cathepsin inhibitors induce cell death in Leishmania major associated with accumulation of debris in autophagy-related lysosome-like vacuoles.
Schurigt U; Schad C; Glowa C; Baum U; Thomale K; Schnitzer JK; Schultheis M; Schaschke N; Schirmeister T; Moll H
Antimicrob Agents Chemother; 2010 Dec; 54(12):5028-41. PubMed ID: 20855728
[TBL] [Abstract][Full Text] [Related]
11. The crystal structure of human cathepsin L complexed with E-64.
Fujishima A; Imai Y; Nomura T; Fujisawa Y; Yamamoto Y; Sugawara T
FEBS Lett; 1997 Apr; 407(1):47-50. PubMed ID: 9141479
[TBL] [Abstract][Full Text] [Related]
12. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.
Marquis RW; Yamashita DS; Ru Y; LoCastro SM; Oh HJ; Erhard KF; DesJarlais RL; Head MS; Smith WW; Zhao B; Janson CA; Abdel-Meguid SS; Tomaszek TA; Levy MA; Veber DF
J Med Chem; 1998 Sep; 41(19):3563-7. PubMed ID: 9733481
[No Abstract] [Full Text] [Related]
13. Rhenium inhibitors of cathepsin B (ReO(SYS)X (where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of inhibition.
Mosi R; Baird IR; Cox J; Anastassov V; Cameron B; Skerlj RT; Fricker SP
J Med Chem; 2006 Aug; 49(17):5262-72. PubMed ID: 16913715
[TBL] [Abstract][Full Text] [Related]
14. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.
Altmann E; Cowan-Jacob SW; Missbach M
J Med Chem; 2004 Nov; 47(24):5833-6. PubMed ID: 15537340
[TBL] [Abstract][Full Text] [Related]
15. Acyclic cyanamide-based inhibitors of cathepsin K.
Barrett DG; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Payne JA; Shewchuk LM; Willard DH; Wright LL
Bioorg Med Chem Lett; 2005 Jun; 15(12):3039-43. PubMed ID: 15896958
[TBL] [Abstract][Full Text] [Related]
16. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi.
Lalmanach G; Mayer R; Serveau C; Scharfstein J; Gauthier F
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):395-9. PubMed ID: 8809025
[TBL] [Abstract][Full Text] [Related]
17. New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8.
Fey P; Chartomatsidou R; Kiefer W; Mottram JC; Kersten C; Schirmeister T
Eur J Med Chem; 2018 Aug; 156():587-597. PubMed ID: 30029081
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cysteine proteases by peptides containing aziridine-2,3-dicarboxylic acid building blocks.
Schirmeister T
Biopolymers; 1999; 51(1):87-97. PubMed ID: 10380356
[TBL] [Abstract][Full Text] [Related]
19. Exploring inhibitor binding at the S' subsites of cathepsin L.
Chowdhury SF; Joseph L; Kumar S; Tulsidas SR; Bhat S; Ziomek E; Ménard R; Sivaraman J; Purisima EO
J Med Chem; 2008 Mar; 51(5):1361-8. PubMed ID: 18278855
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of human cathepsin V.
Somoza JR; Zhan H; Bowman KK; Yu L; Mortara KD; Palmer JT; Clark JM; McGrath ME
Biochemistry; 2000 Oct; 39(41):12543-51. PubMed ID: 11027133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
